Form 8-K - Current report:
SEC Accession No. 0001104659-23-037122
Filing Date
2023-03-27
Accepted
2023-03-27 16:14:34
Documents
12
Period of Report
2023-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310570d1_8k.htm   iXBRL 8-K 26438
  Complete submission text file 0001104659-23-037122.txt   200841

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aytu-20230324.xsd EX-101.SCH 3031
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20230324_lab.xml EX-101.LAB 34477
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20230324_pre.xml EX-101.PRE 22594
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2310570d1_8k_htm.xml XML 3607
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

IRS No.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 23764680
SIC: 2834 Pharmaceutical Preparations